RIC Transplant Using Haplo Donors | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02581007

RIC Transplant Using Haplo Donors
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of graft rejection and acute GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS, chronic GVHD and EFS.

Status: 
Recruiting
Study Date: 
Sun, 11/01/2015 to Wed, 02/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Fludarabine fludarabine (30mg/m2) given every day starting on Day -6 through Day -2; Other Name: Fludara Drug: Melphalan Other Name: melphalan (140mg/m2) given one time on Day -1. Drug: Cyclophosphamide cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4. Other Name: Cytoxan Procedure: peripheral blood stem cell transplant Other Name: HSCT